Breaking News Instant updates and real-time market news.

DXCM

Dexcom

$58.08

0.09 (0.16%)

, ABT

Abbott

$59.19

0.27 (0.46%)

11:22
01/04/18
01/04
11:22
01/04/18
11:22

Dexcom to Underperform at Northland

As previously reported, Northland analyst Suraj Kalia downgraded Dexcom (DXCM) to Underperform from Market Perform after Abbott (ABT) announced Medicare coverage for its Libre FGM. The analyst believes it undercuts Dexcom's competitive advantages, and contends that there is additional headline risk vis-a-vis Medtronic' (MDT) Guardian Connect CGM approval in the pipeline. Further, Kalia believes Dexcom's stock is bound to be under pressure over the next 12-18 months.

DXCM

Dexcom

$58.08

0.09 (0.16%)

ABT

Abbott

$59.19

0.27 (0.46%)

MDT

Medtronic

$83.97

0.05 (0.06%)

  • 04

    Jan

  • 24

    Jan

  • 26

    Feb

DXCM Dexcom
$58.08

0.09 (0.16%)

01/04/18
PIPR
01/04/18
NO CHANGE
PIPR
Dexcom pullback a buying opportunity for longer-term investors, says Piper
Piper Jaffray analyst JP McKim believes Abbott's (ABT) Medicare approval for Libre is "more market-expanding than share-taking" for Dexcom (DXCM), and maintained an Overweight rating on Dexcom shares, seeing the pullback as a buying opportunity for longer-term investors. Dexcom shares are down 8.75% to $53 in late morning trading.
01/04/18
NORL
01/04/18
DOWNGRADE
NORL
Underperform
Dexcom downgraded to Underperform from Market Perform at Northland
12/27/17
PIPR
12/27/17
NO CHANGE
Target $60
PIPR
Overweight
Dexcom can beat Q4 estimates, guidance uncertain, says Piper Jaffray
Piper Jaffray analyst JP McKim believes Dexcom (DXCM) can beat Q4 numbers but he does not have conviction on how management will guide for 2018. His recent channel checks indicate the company has figured out the Medicare processes but that Abbott's (ABT) Libre is gaining "notable adoption" in the type 2 diabetes market. Checks indicate Dexcom has "cracked the Medicare code" in terms of training, billing and getting patients successfully through the pipeline, McKim tells investors in a research note. The analyst, however, expects more headline volatility for the shares around the Libre launch. He continues to recommend investors with a time horizon beyond a year buy the stock. The analyst keeps an Overweight rating on Dexcom with a $60 price target.
12/21/17
JEFF
12/21/17
NO CHANGE
JEFF
Jefferies lays out top 2018 ideas in Medical Supplies & Devices
Jefferies analyst Raj Denhoy calls Haemonetics (HAE), AxoGen (AXGN), Abbott (ABT) and Hologic (HOLX) his top Medical Supplies & Devices ideas to start 2018. Following a year of strong device performance in 2017, the analyst believes 2018 is "looking like more of the same." Denhoy raised his price target for Abiomed (ABMD) to $220, for Dexcom (DXCM) to $70, for Haemonetics to $68, for Hologic to $52, for LivaNova (LIVN) to $94, for Varex Imaging (VREX) to $44 and for Zimmer Biomet (ZBH) to $140. The analyst has Buy ratings on all of those stocks.
ABT Abbott
$59.19

0.27 (0.46%)

01/03/18
EVER
01/03/18
INITIATION
Target $64
EVER
Outperform
Abbott initiated with an Outperform at Evercore ISI
Evercore ISI analyst Vijay Kumar started Abbott Laboratories with an Outperform rating and $64 price target. The analyst sees more room for shares to run in 2018 as the company's sales growth accelerates to the 5%-6% range.
01/04/18
LEHM
01/04/18
UPGRADE
Target $135
LEHM
Overweight
Edwards Lifesciences upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Matthew Taylor upgraded Edwards Lifesciences (EW) to Overweight and raised his price target for the shares to $135 from $125. The company can "bridge risks in 2018 to exciting growth drivers in 2019," Taylor tells investors in a research note. The analyst's top pick in U.S. Medical Supplies & Devices remains Abbott (ABT).
01/02/18
01/02/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. L Brands (LB) upgraded to Outperform from Neutral at Baird with analyst Mark Altschwagern saying he believes the company is on track to meet or exceed December comparable sales and fourth quarter expectations. 2. Lennar (LEN) upgraded to Outperform from Market Perform at Wells Fargo with analyst Stephen East citing his post-tax reform earnings per share estimate but without the CalAtlantic (CAA) acquisition included. 3. Disney (DIS), Netflix (NFLX), AMC Networks (AMCX), and Discovery (DISCA) were upgraded to Outperform from Neutral at Macquarie. 4. Abbott (ABT) was upgraded to Overweight from Equal Weight at Morgan Stanley and to Overweight from Neutral at JPMorgan. 5. Baxter (BAX) was upgraded to Buy from Neutral at BofA/Merrill and to Overweight from Neutral at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MDT Medtronic
$83.97

0.05 (0.06%)

12/15/17
PIPR
12/15/17
NO CHANGE
Target $90
PIPR
Overweight
NuVasive's new lateral ALIF system underappreciated, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien views NuVasive's new lateral anterior lumbar interbody fusion procedure as an underappreciated revenue driver for the company. This as an important introduction for NuVasive as it finally allows the company to access the lower lumbar region with less invasiveness, O'Brien tells investors in a research note. He notes the product will allow NuVasive to compete head-to-head with Medtronic's (MDT) OLIF procedure, which he believes has grown quickly. O'Brien sees the lateral ALIF system adding $30M-$50M to NuVasive sales over the next three to four years, helping to push the stock higher. He keeps an Overweight rating on the stock with a $90 price target.
01/03/18
EVER
01/03/18
INITIATION
Target $92.5
EVER
Outperform
Medtronic initiated with an Outperform at Evercore ISI
Evercore ISI analyst Vijay Kumar started Medtronic with an Outperform rating and $92.50 price target. The analyst has confidence in the company's revenue growth accelerating in the second half of 2018. He finds the stock "compelling" at current share levels.
01/02/18
BOFA
01/02/18
UPGRADE
BOFA
Buy
Medtronic upgraded to Buy from Neutral at BofA/Merrill
01/02/18
BOFA
01/02/18
UPGRADE
BOFA
Buy
Medtronic upgraded to Buy at BofA/Merrill
As previously reported, BofA/Merrill upgraded Medtronic to Buy from Neutral and increased its price target to $94 from $90. Analyst Bob Hopkins believes Medtronic is on the "verge" of delivering more consistent growth driven by its pipeline and manufacturing footprint reduction, which should drive multiple expansion.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

14:17
04/25/18
04/25
14:17
04/25/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
04/25/18
04/25
14:16
04/25/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

$74.84

-0.45 (-0.60%)

14:16
04/25/18
04/25
14:16
04/25/18
14:16
Technical Analysis
Technical Take: PayPal has a potential topping pattern ahead of earnings »

Ahead of earnings the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 22

    May

  • 23

    May

  • 12

    Jun

DXC

DXC Technology

$102.23

-0.8 (-0.78%)

14:15
04/25/18
04/25
14:15
04/25/18
14:15
Options
DXC Technology put volume heavy and directionally bearish »

Bearish flow noted in DXC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

14:14
04/25/18
04/25
14:14
04/25/18
14:14
Hot Stocks
Maryland announces $35M settlement with Volkswagen over defeat devices »

Maryland Attorney General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACAD

Acadia

$18.82

-0.66 (-3.39%)

14:10
04/25/18
04/25
14:10
04/25/18
14:10
Hot Stocks
Acadia falls after FDA said to open re-examination of Parkinson's drug »

Shares of Acadia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$11.02

0.07 (0.64%)

, GM

General Motors

$37.80

-0.12 (-0.32%)

14:07
04/25/18
04/25
14:07
04/25/18
14:07
Earnings
On The Fly: What to watch in auto space earnings reports »

Ford (F) and General…

F

Ford

$11.02

0.07 (0.64%)

GM

General Motors

$37.80

-0.12 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 01

    May

  • 20

    Jun

TWTR

Twitter

$29.24

-1.24 (-4.07%)

14:05
04/25/18
04/25
14:05
04/25/18
14:05
Upgrade
Twitter rating change  »

Twitter upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    May

  • 27

    Jul

TMUS

T-Mobile

$63.95

1.37 (2.19%)

14:05
04/25/18
04/25
14:05
04/25/18
14:05
Options
T Mobile call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPKE

Spark Energy

$11.78

0.025 (0.21%)

14:04
04/25/18
04/25
14:04
04/25/18
14:04
Periodicals
Breaking Periodicals news story on Spark Energy »

Spark Energy said to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 10

    May

ACAD

Acadia

$19.95

0.47 (2.41%)

14:00
04/25/18
04/25
14:00
04/25/18
14:00
Periodicals
FDA head says will 'take another look' at Acadia's Nuplazid, CNN reports »

In response to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$304.83

-2.41 (-0.78%)

13:58
04/25/18
04/25
13:58
04/25/18
13:58
Conference/Events
Netflix management to meet with UBS »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

MSFT

Microsoft

$92.23

-0.85 (-0.91%)

13:55
04/25/18
04/25
13:55
04/25/18
13:55
Conference/Events
House Appropriations Committee to hold a hearing »

The Labor, Health &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

ZOOM

Zoom Technologies

13:55
04/25/18
04/25
13:55
04/25/18
13:55
Conference/Events
Zoom Technologies participates in a conference call with RBC Capital »

RBC Capital Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

JD

JD.com

$35.84

-0.03 (-0.08%)

13:50
04/25/18
04/25
13:50
04/25/18
13:50
Options
Volatility play in JD as January puts trade in large blocks Wednesday »

Volatility play in JD as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:50
04/25/18
04/25
13:50
04/25/18
13:50
General news
Treasury Curve Action: steepeners resumed »

Treasury Curve Action:…

AMD

AMD

$9.69

-0.4 (-3.96%)

13:40
04/25/18
04/25
13:40
04/25/18
13:40
Options
Aggresive buyer lays out $2.2M for deep in the money Advanced Micro puts »

Aggresive buyer lays out…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 02

    May

AAPL

Apple

$164.70

1.83 (1.12%)

13:40
04/25/18
04/25
13:40
04/25/18
13:40
Conference/Events
President Trump to meet with Apple CEO Cook »

The meeting between…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 01

    May

WELL

Welltower

$49.86

-1.16 (-2.27%)

, QCP

Quality Care Properties

$21.35

0.55 (2.64%)

13:37
04/25/18
04/25
13:37
04/25/18
13:37
Periodicals
Promedica, Welltower offering $2B to aquire Quality Care Properties, Reuters says »

Promedica and Welltower…

WELL

Welltower

$49.86

-1.16 (-2.27%)

QCP

Quality Care Properties

$21.35

0.55 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 03

    May

  • 04

    May

EBAY

eBay

$40.63

-0.55 (-1.34%)

13:36
04/25/18
04/25
13:36
04/25/18
13:36
Technical Analysis
Technical Earnings Preview: eBay in uptrend ahead of earnings »

The shares have been in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LC

LendingClub

$2.78

-0.485 (-14.85%)

13:36
04/25/18
04/25
13:36
04/25/18
13:36
Hot Stocks
LendingClub calls charges in FTC complaint 'legally and factually unwarranted' »

Following an inquiry that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

LC

LendingClub

$2.78

-0.485 (-14.85%)

13:36
04/25/18
04/25
13:36
04/25/18
13:36
Hot Stocks
Breaking Hot Stocks news story on LendingClub »

LendingClub calls charges…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

FB

Facebook

$160.15

0.49 (0.31%)

, GOOG

Alphabet

$1,021.04

1.58 (0.15%)

13:35
04/25/18
04/25
13:35
04/25/18
13:35
Periodicals
Facebook declines to testify at U.S. House hearing on social media, Reuters says »

A Facebook (FB) spokesman…

FB

Facebook

$160.15

0.49 (0.31%)

GOOG

Alphabet

$1,021.04

1.58 (0.15%)

GOOGL

Alphabet Class A

$1,023.95

0.97 (0.09%)

TWTR

Twitter

$28.98

-1.5 (-4.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 30

    May

  • 27

    Jul

HOG

Harley-Davidson

$41.88

-0.13 (-0.31%)

13:30
04/25/18
04/25
13:30
04/25/18
13:30
Options
Hefty spread opened in Harley Davidson options »

Hefty spread opened in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

TWTR

Twitter

$28.97

-1.51 (-4.95%)

13:29
04/25/18
04/25
13:29
04/25/18
13:29
Recommendations
Twitter analyst commentary  »

Twitter outlook looks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    May

  • 27

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.